<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807963</url>
  </required_header>
  <id_info>
    <org_study_id>HZ2-08-02</org_study_id>
    <nct_id>NCT00807963</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone</brief_title>
  <official_title>Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated concentration (MTC) of&#xD;
      bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate&#xD;
      without rHuPH20 administered SC, the optimal dose of rHuPH20 to deliver bisphosphonate SC at&#xD;
      MTC, and to compare the PK of SC administered bisphosphonate at MTC with optimal dose rHuPH20&#xD;
      to bisphosphonate alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 21, 2009</completion_date>
  <primary_completion_date type="Actual">September 21, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of local tolerability of injected drug product</measure>
    <time_frame>Over a 7 day period</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Risk Factors for or a Diagnosis of Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Stage 1: rHuPH20 plus ZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: ZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose/concentration of ZA administered without rHuPH20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: rHuPH20 plus ZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one of several dose/concentrations of rHuPH20 with ZA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4: ZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4: ZA with rHuPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>recombinant human hyaluronidase PH20 injection</description>
    <arm_group_label>Stage 1: rHuPH20 plus ZA</arm_group_label>
    <arm_group_label>Stage 3: rHuPH20 plus ZA</arm_group_label>
    <arm_group_label>Stage 4: ZA with rHuPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Stage 1: rHuPH20 plus ZA</arm_group_label>
    <arm_group_label>Stage 2: ZA</arm_group_label>
    <arm_group_label>Stage 3: rHuPH20 plus ZA</arm_group_label>
    <arm_group_label>Stage 4: ZA</arm_group_label>
    <arm_group_label>Stage 4: ZA with rHuPH20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers 18 to 60 years of age, inclusive.&#xD;
&#xD;
          -  Intact normal skin in the area intended for administration.&#xD;
&#xD;
          -  Adequate venous access in both upper extremities.&#xD;
&#xD;
          -  Dental examination by an appropriately trained professional within 14 days of&#xD;
             administration demonstrating no signs, symptoms, or risk factors of osteonecrosis of&#xD;
             the jaw (ONJ).&#xD;
&#xD;
          -  Vital signs (BP, HR, temperature, respiratory rate) within normal range or, if out of&#xD;
             range, assessed by the Investigator as not clinically significant and it is mutually&#xD;
             agreed by both Investigator and Sponsor Medical Monitor that the subject need not be&#xD;
             excluded from the study for this reason.&#xD;
&#xD;
          -  Electrocardiogram within normal range or if out of range, assessed by the Investigator&#xD;
             as not clinically significant and it is mutually agreed by both Investigator and&#xD;
             Sponsor Medical Monitor that the subject need not be excluded from the study for this&#xD;
             reason.&#xD;
&#xD;
          -  Within 14 days prior to administration, metabolic panel (e.g., sodium, potassium,&#xD;
             chloride, bicarbonate, BUN, creatinine, glucose, calcium, AST, ALT, alkaline&#xD;
             phosphatase, total bilirubin, albumin, and total protein) and complete blood count&#xD;
             within the laboratory normal reference range or, if out of range, assessed by the&#xD;
             Investigator as not clinically significant and it is mutually agreed by both&#xD;
             Investigator and Sponsor Medical Monitor that the subject need not be excluded from&#xD;
             the study for this laboratory value.&#xD;
&#xD;
          -  A negative serum or urine pregnancy test (if female of child-bearing potential) within&#xD;
             14 days of study drug administration.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must agree to be currently practicing&#xD;
             effective birth control or abstinence and agree to continue to do so for at least 30&#xD;
             days after duration of their time on study.&#xD;
&#xD;
          -  Decision-making capacity and willingness and ability to comply with the requirements&#xD;
             for full completion of the trial.&#xD;
&#xD;
          -  Signed, written IRB/EC-approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lower extremity edema.&#xD;
&#xD;
          -  Lower extremity pathology that could interfere with any protocol-specified outcome&#xD;
             assessment (e.g., cellulitis, lymphatic disorder or prior surgery, pre-existing pain&#xD;
             syndrome, auxiliary lymph node dissection, etc.).&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min (Cockcroft-Gault formula).&#xD;
&#xD;
          -  Any risk factor for bisphosphonate-related renal toxicity including by not limited to&#xD;
             known predisposition to or history of renal insufficiency or renal failure,&#xD;
             hypertension, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and&#xD;
             subjects receiving known nephrotoxic drugs.&#xD;
&#xD;
          -  Dehydration Grade 2 or higher based on NCI CTCAE V3.0.&#xD;
&#xD;
          -  Known parathyroid gland dysfunction or any other disease that could lower blood&#xD;
             calcium levels.&#xD;
&#xD;
          -  Known history and/or electrocardiographic evidence of atrial fibrillation.&#xD;
&#xD;
          -  Known allergy to any hyaluronidase.&#xD;
&#xD;
          -  Bisphosphonate treatment within preceding six months.&#xD;
&#xD;
          -  Known allergy or intolerance to any bisphosphonate.&#xD;
&#xD;
          -  Pregnancy or breast-feeding woman.&#xD;
&#xD;
          -  Known clinically significant cardiovascular, gastrointestinal, hepatic, neurological,&#xD;
             psychiatric, endocrine, cancer, HIV infection, diabetes mellitus, intercurrent illness&#xD;
             such as influenza, or other major systemic disease that would unduly risk the&#xD;
             subject's safety or interfere with the interpretation of results.&#xD;
&#xD;
          -  Participation in a study of any investigational drug or device within 30 days of&#xD;
             enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel P DeNoia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Healthcare Discoveries, LLC/ICON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, LLC/ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>rHuPH20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

